COPD this Week

A forum for the exchange of views and knowledge on COPD

[ERS publications @ERSpublications]

ERR: This meta-analysis (111 studies) quantifies viral prevalence in acute/stable asthma in children and adults, and highlights links between specific viruses and acute asthma severity. PCR alone may be limited in identifying viral acute asthma triggers. https://t.co/9BgxQTDRor

[MathioudakisAG @MathioudakisAG]

🚨 Clinical academics undertake years of additional research training — but this is not recognised in NHS consultant pay progression.

This creates a structural inconsistency → ~£72,000–£81,000 lifetime loss per research year during training.

📖https://t.co/GGhBIpum4T

[MathioudakisAG @MathioudakisAG]

🫁📘 New in Thorax

Stopping COPD maintenance inhalers is not neutral.

In a post-hoc FLAME analysis, discontinuing LAMA or ICS was associated with a disproportionate early rise in exacerbations, concentrated in the first ~3 months — consistent with true withdrawal effects.

📊👇

[ERS @EuroRespSoc]

ERS Vision Live: ERS Congress 2025 highlights for COPD specialists

Join Dr Sheila Ramjug and Dr Eva Polverino as they speak with Dr Alexander Mathioudakis about the highlights for COPD specialists from the ERS Congress 2025.

Watch: https://t.co/EGvZjq3puI

[MathioudakisAG @MathioudakisAG]

👉 Ex-smokers with high BEC (≥200) do benefit from LABA+ICS
🚭 But current smokers? Minimal ICS response.
📊 Smoking status modifies ICS efficacy

@JensUlrikJensen
@victoriachgr
@ManchesterBRC
@UoM_DIIIRM

[MathioudakisAG @MathioudakisAG]

🔥 Our new analysis from the #FLAMEtrial - just published @ThoraxBMJ:
📉 Reduced treatment response to inhaled corticosteroids in current smokers with COPD, regardless of blood eosinophil count: Insights from the FLAME trial.

https://t.co/mmI5p1ub3I

[ERS @EuroRespSoc]

Voting has opened for the ERS Leadership Elections 2025! 🗳️

The elections provide ERS members with the opportunity to have their say in the development of ERS. Voting closes on 22 June, 2025.

ERS members can visit the 'Elections' tab on myERS to vote: https://t.co/Bo5R5hRYqD

[MathioudakisAG @MathioudakisAG]

🚀 Introducing the ICS‑RECODE research programme: An IPD meta‑analysis aimed at identifying predictors of response to inhaled corticosteroids (#ICS) in #COPD. Our work builds on data from 22 RCTs with over 50,000 participants.

[MathioudakisAG @MathioudakisAG]

🚨Rethinking Blood Eosinophils (BEC) for Assessing #ICS Response in #COPD: A Post-Hoc Analysis from #FLAME.

- BEC change during ICS treatment predicts treatment response to ICS in COPD.
- BEC measured on ICS treatment misclassify 9% of patients.
@journal_CHEST
@ManchesterBRC

[MathioudakisAG @MathioudakisAG]

Dear friends and colleagues, I am excited to share that I'm running for Chair of ERS Group 5.1 (Airway Pharmacology and Treatment). I would be grateful of your support!! 🗳️🗳️
@ManchesterBRC @UoM_DIIIRM @MFT_Research

[Corlateanu Alexandru @ACorlateanu]

Combined Pulmonary Fibrosis and Emphysema: Comparative Evidence on a Complex Condition https://t.co/D6kEHNYLy5 #mdpibiomedicines via @Biomed_MDPI

[MathioudakisAG @MathioudakisAG]

In a meta-analysis of 24 RCTs (N=2192), we found that mucolytics can improve treatment success rate by 37% and improve symptoms in COPD exacerbations #AECOPD (moderate certainty). https://t.co/njnLwneBL8

@ProfJVestbo @ManchesterBRC @UoM_DIIIRM @MFT_Research @ERSpublications

[MathioudakisAG @MathioudakisAG]

How to peer review: Practical advice for early career researchers.
@OrianneDumas @EarlyCareerERS @ERSpublications
https://t.co/nt2R110ZDM

[MathioudakisAG @MathioudakisAG]

The @EuroRespSoc COPD Exacerbations Core Outcome Set is published in this months issue of the ERJ @ERSpublications. It is endorsed by @EuroRespSoc @atscommunity @ALATorax @patscommunity. https://t.co/h36cAPZsfH
@ProfJVestbo @DoctorJensUlrik @prw_paula @ManchesterBRC @FBMH_UoM

[MathioudakisAG @MathioudakisAG]

New Pre-Print:
Prognostic factors for mortality, ICU and hospital admission due to COVID-19 in Europe.
A meta-analysis of age & gender adjusted data, to minimize potential bias.
@VardavasC @ProfJVestbo @ManchesterBRC
More info: https://t.co/xOA3NDuRFh

[Katerina Antoniou @Katerin16265046]

ERS Satellites!!! Great experience!
Many thanks to ERS and Hellenic Thoracic Society!

[MathioudakisAG @MathioudakisAG]

Top cited non-COVID related paper 2021 @ThoraxBMJ:
Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits.
https://t.co/IBkxpTOlld
@wjanss0 @pradsiv @SinganayagamLab @realmdransfield @DoctorJensUlrik @ProfJVestbo

[ThoraxBMJ @ThoraxBMJ]

Effects of switching from a metered dose inhaler to a dry powder inhaler on climate emissions and asthma control: post-hoc analysis https://t.co/5mfSzQoRPn